GlassScriptPhysician profile
Ginger S Kubala
NPI 1952441891
$18,947.79
in general payments reported to CMS, 2019-2025
61 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $1,519 · 2021: $2,952 · 2022: $2,852 · 2023: $3,346 · 2024: $3,332 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,038.20 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,344.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,244.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $2,162.06 | 2019-2025 | |
| Lilly USA, LLC | $1,135.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,054.01 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $834.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $777.65 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $586.28 | 2021-2025 | |
| Astellas Pharma US INC | $536.85 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.94 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $456.84 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $395.67 | 2023-2025 | Gemtesa |
| Mannkind Corporation | $382.02 | 2019-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $352.28 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $351.70 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Kubala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.